



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/40, 47/12, 47/26		A1	(11) International Publication Number: WO 99/44604
			(43) International Publication Date: 10 September 1999 (10.09.99)
(21) International Application Number: PCT/US99/04516 (22) International Filing Date: 2 March 1999 (02.03.99) (30) Priority Data: 60/076,659 3 March 1998 (03.03.98) US (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 60/076,659 (CIP) Filed on 3 March 1998 (03.03.98) (71) Applicant (for all designated States except US): SHIONOGI & CO., LTD. [JP/JP]; 1-8, Doshomachi 3-chome, Chuo-ku, Osaka 553-0002 (JP). (72) Inventors; and (75) Inventors/Applicants (for US only): CONFER, William, Lester [US/US]; 5144 Red Yarrow Way, Indianapolis, IN 46254 (US). TAI, Hideaki [JP/JP]; 1-16-27-706, Mikunihon-machi, Yodogawa-ku, Osaka-shi, Osaka 532-0005 (JP). (74) Agents: MAEBIUS, Stephen, B. et al.; Foley & Lardner, Suite 500, 3000 K. Street, N.W., Washington, DC 20007-5109 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(54) Title: PHARMACEUTICAL COMPOSITIONS CONTAINING THE PHOSPHOLIPASE INHIBITOR SODIUM [[3-(2-AMINO-1,2-DIOXOETHYL)-2-ETHYL-1-PHENYLMETHYL]-1H-INDOL-4-YL]OXY]ACETATE			
(57) Abstract A lyophilized pharmaceutical composition is described which contains Sodium [[3- (2-amino- 1,2-dioxoethyl)- 2-ethyl-1-phenylmethyl)- 1H-indol-4- yl]oxy]acetate, a Solubilizer, and Stabilizer. Such compositions are storage stable and readily dissolve in aqueous medium to give injectable solution for treatment of sepsis, etc.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

PHARMACEUTICAL COMPOSITIONS CONTAINING THE PHOSPHOLIPASE INHIBITOR SODIUM
[[3-(2-AMINO-1,2-DIOXOETHYL)-2-ETHYL-1-PHENYLMETHYL]-1H-INDOL-4-YL]OXY]ACETATE

Field of the Invention

This invention relates to pharmaceutical compositions containing a phospholipase inhibitor, more particularly, to a more stable pharmaceutical composition which contains sodium [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetate as an active ingredient.

Background

Sodium [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetate (hereinafter referred to as Compound (I) or Active Ingredient in this specification) is a useful compound as an inhibitor against human non-pancreatic secretory phospholipase A2 (hereinafter referred to as sPLA2), as disclosed in JP-A 7-285933, European Patent Application No. 95302166.4 (EP Publ. No. 0 675 110 A1) and US Patent No. 5,654,326; the disclosures of which are incorporated herein by reference.

Medicaments for injections are usually formulated into not only emulsions, suspensions or solutions, but also lyophilized preparations to be dissolved before use which are stable, can be preserved and are easily reconstituted. As is generally known to those skilled in the art, it is easy to keep the lyophilized preparations sterile and eliminate foreign insoluble matter from the lyophilized preparations.

Concerning injectable preparations, JP-A 7-285933 discloses an isotonic saline solution of Compound (I) at a concentration of 0.1 g/L and a method to intravenously infuse the saline solution but

does not disclose any compositions like those of the present invention. A stable pharmaceutical preparation of Compound (I), in particular, a stable injectable preparation of Compound (I) or a lyophilized preparation of Compound (I) for preparing injectable preparations has long been desired.

Storage of a pharmaceutical composition of Compound (I) prepared by known methods may lead to degradation of its content and a coloring and a worsening of its reconstitution properties, especially in the case of injections to be dissolved before use. It is difficult to provide a pharmaceutical composition of Compound (I) which has good stability and a good reconstitution property, especially for injections of Compound (I) to be dissolved before use, after long storage at room temperature. In more detail, as Compound (I) is a sparingly soluble compound, it is difficult to obtain a clear solution of Compound (I) by only mixing the Compound (I) with a solvent, which makes it desirable to obtain an injection solution and a processing solution.

Even if a clear solution of Compound (I) were obtained by changing conditions such as temperature and the like, degradation of a solution of Compound (I) and a clouding would occur after long storage, resulting in degradation and non-uniform contents of Compound (I) in the solution or the lyophilized injectable preparation of Compound (I). One of the problems to be solved by the present invention is to keep Compound (I) stable in aqueous carriers.

Preparing lyophilized products by the methods of the prior art sometimes causes problems in quality. These problems include a sublimation of some ingredients coinciding with that of water, content of ingredients decreases in the lyophilized product, a partial solidifying of product, lyophilized preparations are cracked and shrunk and may have a thin layer on the top of the cake, adherence to the upper portion of vials and spatters, and

non-uniform appearance of lyophilized cakes. Pharmacists and the like require injections to be dissolved in an infusion solution before use, for example, a lyophilized injection should have good reconstitution properties.

Another problem to be solved by the present invention is to provide an excellent lyophilized preparation of Compound (I) of good quality with a uniform appearance, good reconstitution and no degradation of its contents during storage.

Summary

The inventors of the present invention studied various additive agents for preparations of Compound (I) to solve the problems mentioned above. As a result, by adding a Solubilizer, preferably together with a Stabilizer, in a preparation with Compound (I), the present inventors discovered improved preparations of Compound (I) having desired qualities such as no degradation of the contents, good stability, a uniform appearance and a good reconstitution property.

This invention is a storage stable solid lyophilized composition of Compound (I) suitable for making a liquid useful for treatment of Inflammatory Diseases (including sepsis) in mammals.

This invention is also an aqueous solution of a lyophilized composition of Compound (I) useful for the treatment of Inflammatory Diseases (including sepsis) in mammals.

This invention is also a method of making a storage stable and easily reconstituted lyophilized composition of Compound (I).

This invention is also an improved method of treating Inflammatory Diseases in mammals using the lyophilized composition of Compound (I).

This invention is also a unit dosage IV bag or bottle containing a lyophilized composition of Compound (I) dissolved in

aqueous medium at a concentration suitable for direct injection into a mammal for treatment of Inflammatory Diseases (including sepsis).


This invention is a dose-concentrate sealed container containing a solid lyophilized composition of Compound (I).

Detailed Description

Definitions:

The term, "lyophilized composition(s)" refers to the solid freeze-dried composition of matter prepared by the process of this invention and comprising as essential ingredients: (1) sodium [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetate; (2) a Solubilizer; and (3) a Stabilizer.

The term, "Active Ingredient" (also called "Compound (I)") refers to the compound, sodium [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetate, a compound represented by the formula:



The term, "mammal", includes a human as well as related important veterinary species of mammals, domesticated quadrupeds such as monkeys, dogs, cats, horses, sheep, pigs, goats, and cows.

The term, "Inflammatory Diseases" refers to diseases such as inflammatory bowel disease, sepsis, septic shock, adult respiratory distress syndrome, pancreatitis, trauma-induced shock, bronchial asthma, allergic rhinitis, rheumatoid arthritis, cystic fibrosis, stroke, acute bronchitis, chronic bronchitis, acute bronchiolitis, chronic bronchiolitis, osteoarthritis, gout, spondylarthropathris, ankylosing spondylitis, Reiter's syndrome, psoriatic arthropathy, enteropathic spondylitis, Juvenile arthropathy or juvenile ankylosing spondylitis, Reactive arthropathy, infectious or post-infectious arthritis, gonococcal arthritis, tuberculous arthritis, viral arthritis, fungal arthritis, syphilitic arthritis, Lyme disease, arthritis associated with "vasculitic syndromes," polyarteritis nodosa, hypersensitivity vasculitis, Luegenec's granulomatosis, polymyalgin rheumatica, joint cell arteritis, calcium crystal deposition arthropathris, pseudo gout, non-articular rheumatism, bursitis, tenosynovitis, epicondylitis (tennis elbow), carpal tunnel syndrome, repetitive use injury (typing), miscellaneous forms of arthritis, neuropathic joint disease (charco and joint), hemarthrosis (hemarthrosic), Henoch-Schonlein Purpura, hypertrophic osteoarthropathy, multicentric reticulohistiocytosis, arthritis associated with certain diseases, surcoilosis, hemochromatosis, sickle cell disease and other hemoglobinopathries, hyperlipoproteineimia, hypogammaglobulinemia, hyperparathyroidism, acromegaly, familial Mediterranean fever, Behat's Disease, systemic lupus erythrematosis, or relapsing polychondritis and related diseases included or maintained by sPLA₂ mediated release of fatty acid and the arachidonic acid cascade and its deleterious products.

The term, "collapse temperature," describes the glass transition temperature for amorphous solids or eutectic temperature for crystalline solids. Collapse temperature is that

temperature above which the product is not completely frozen. Freeze dry microscopy enables measurement of the temperature at which frozen solutions begin to lose their rigid structure during a sublimation process. For sodium [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetate frozen solutions, the collapse temperature before annealing has been measured at about -33°C while the collapse temperature after annealing is about -13°C.

The term, "Solubilizer", refers to a chelating agent. An "effective amount of Solubilizer" is a quantity of Solubilizer that permits the Active Ingredient to form stable aqueous solutions suitable for medical use.

The term, "Stabilizer", refers to a solid sugar or sugar-alcohol. An "effective amount of Stabilizer" is a quantity of Stabilizer that permits the lyophilized composition to be readily dissolved to form aqueous solutions suitable for medical use.

The term, "dose-concentrate" refers to a solution of pharmaceutical formulation. The dose-concentrate may be held in the container where it was formed by adding aqueous solvent to pharmaceutical formulation or it may be removed and held externally. The dose-concentrate may be used as is, but is generally further diluted to a unit dosage concentration for administration to a mammal. The entire volume of the dose-concentrate or aliquots thereof may be used in preparing unit dose(s) for treatment by the method of this invention.

The term, "the equivalent acid of Active Ingredient" or "the equivalent acid of Compound (I)" means [[3-(2-Amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid. In this specification, weight of Active Ingredient is shown by the actual weight of sodium [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetate. In showing proportion (weight %) of Active ingredient, however, it is


calculated based on the equivalent acid of Active Ingredient. Thus weights of Active Ingredient must be multiplied by the factor 100/105.8 to calculate the equivalent weight of the equivalent acid.

Methods of Making the Active Ingredient:

Compound (I) to be used in the present invention can be synthesized by the known process described in JP-A 7 285933 and can be used for the compositions and preparations of the present invention in any state, including crystal, amorphous, hydrate, solvate, or a mixture of such forms. Similarly, Compound (I) may be prepared by the synthesis schemes taught in US Patent No. 5,654,326; the disclosure of which is incorporated herein by reference. Another method of making Compound (I) is described in United States Patent Application Serial No. 09/105381, filed June 26, 1998 and titled, "Process for Preparing 4-substituted 1-H-Indole-3-glyoxyamides" the entire disclosure of which is incorporated herein by reference.

An illustrative synthesis of Compound (I) is as follows in Steps (A) through (F):

Preparation of Sodium [[3-(2-Amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetate, a compound represented by the formula:



Step A. Preparation of 2-Ethyl-4-methoxy-1H-indole:

A solution of 140 mL (0.18 mol) of 1.3M sec-butyl lithium in cyclohexane was added slowly to N-tert-butoxycarbonyl-3-methoxy-2-methylaniline (21.3g, 0.09 mol) in 250 mL of THF keeping the temperature below -40°C with a dry ice-ethanol bath. The bath was removed and the temperature allowed to rise to 0°C and then the bath replaced. After the temperature had cooled to -60°C, 18.5g (0.18 mol) of N-methoxy-N-methylpropanamide in an equal volume of THF was added dropwise. The reaction mixture was stirred 5 minutes, the cooling bath removed and stirred an additional 18 hours. It was then poured into a mixture of 300 mL of ether and 400 mL of 0.5N HCl. The organic layer was separated, washed with water, brine, dried over MgSO₄, and concentrated at reduced pressure to give 25.5g of a crude of 1-[2-(tert-butoxycarbonylamino)-6-methoxyphenyl]-2-butanone. This material was dissolved in 250 mL of methylene chloride and 50 mL of trifluoroacetic acid and stirred for a total of 17 hours. The mixture was

concentrated at reduced pressure and ethyl acetate and water added to the remaining oil. The ethyl acetate was separated, washed with brine, dried (MgSO_4) and concentrated. The residue was chromatographed three times on silica eluting with 20% EtOAc/hexane to give 13.9g of 2-ethyl-4-methoxy-1H-indole.

Step B. Preparation of 2-Ethyl-4-methoxy-1-(phenylmethyl)-1H-indole:

2-Ethyl-4-methoxy-1H-indole (4.2g, 24 mmol) was dissolved in 30 mL of DMF and 960mg (24 mmol) of 60% NaH/mineral oil was added. After 1.5 hours, 2.9 mL (24 mmol) of benzyl bromide was added. After 4 hours, the mixture was diluted with water and extracted twice with ethyl acetate. The combined ethyl acetate was washed with brine, dried (MgSO_4) and concentrated at reduced pressure. The residue was chromatographed on silica gel and eluted with 20% EtOAc/hexane to give 3.1g (49% yield) of 2-ethyl-4-methoxy-1-(phenylmethyl)-1H-indole.

Step C. Preparation of 2-Ethyl-4-hydroxy-1-(phenylmethyl)-1H-indole:

3.1g (11.7 mmol) of 2-ethyl-4-methoxy-1-(phenylmethyl)-1H-indole was O-demethylated by treating it with 48.6 mL of 1M BBr_3 in methylene chloride with stirring at room temperature for 5 hours, followed by concentration at reduced pressure. The residue was dissolved in ethyl acetate, washed with brine and dried (MgSO_4). After concentrating at reduced pressure, the residue was chromatographed on silica gel eluting with 20% EtOAc/hexane to give 1.58g (54% yield) of 2-ethyl-4-hydroxy-1-(phenylmethyl)-1H-indole.

Step D: Preparation of [[2-Ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid methyl ester.

2-ethyl-4-hydroxy-1-(phenylmethyl)-1H-indole (1.56g, 6.2 mmol) was added to a mixture of 248mg (6.2 mmol) of 60% NaH/mineral oil in 20mL DMF and stirred for 0.67 hour.

Then 0.6 mL(6.2 mmol) of methyl bromoacetate was added and stirring was continued for 17 hours. The mixture was diluted with water and extracted with ethyl acetate. The ethyl acetate solution was washed with brine, dried (MgSO_4), and concentrated at reduced pressure. The residue was chromatographed on silica gel eluting with 20% EtOAc/hexane, to give 1.37g (69% yield) of [[2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid methyl ester.

Step E. Preparation of [[3-(2-Amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid methyl ester:

Oxalyl chloride (0.4 mL, 4.2 mmol) was added to 1.36g (4.2 mmol) of [[2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid methyl ester in 10 mL of methylene chloride and the mixture stirred for 1.5 hours. The mixture was concentrated at reduced pressure and residue taken up in 10 mL of methylene chloride. Anhydrous ammonia was bubbled in for 0.25 hours, the mixture stirred for 1.5 hours and evaporated at reduced pressure. The residue was stirred with 20 mL of ethyl acetate and the mixture filtered. The filtrate was concentrated to give 1.37g of a mixture of [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid methyl ester and ammonium chloride. This mixture melted at 172-187°C.

Step F. Preparation of [[3-(2-Amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid, sodium salt:

A mixture of 788 mg (2 mmol) of [3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-acetic acid methyl ester, 10 mL of 1N NaOH and 30 mL of MeOH is heated to maintain reflux for 0.5 hour, stirred at room temperature for 0.5 hour and concentrated at reduced pressure.

Identity and Proportion of Ingredients in the
Pharmaceutical Compositions and Lyophilized Compositions of
the Invention:

In one embodiment, the present invention is a pharmaceutical composition which comprises Compound (I) as Active Ingredient and an effective amount of a Solubilizer acting as a chelating agent, for example, preferably at least one compound selected from citric acid, edetic acid (e.g., disodium EDTA), polyphosphoric acid and their salts, more preferably sodium citrate. Examples of polyphosphoric acid and their salts are potassium polyphosphate as described in the Japanese standards of food additives, 6th ed., and sodium polyphosphate as described in the Japanese standards of food additives, 6th ed., or the Japanese standards of cosmetic ingredients, 2nd ed. Sodium citrate is available as trisodium citrate anhydrous, trisodium citrate dihydrate, and trisodium citrate pentahydrate, but is most conveniently and preferably used in the form of trisodium citrate dihydrate (mol. wt. 294.10).

The amount of the Solubilizer varies with the kind of the Solubilizer and the concentration of Compound (I), and may be from about 1% to about 400% (w/w), preferably 1 to 200 % (w/w), most preferably 1 to 100 % (w/w) of the amount of the equivalent acid of Compound (I). For pharmaceutical compositions using sodium

citrate the weight of Solubilizer is from 10% to 150% (w/w) and more preferably 25% to 100% (w/w) of the amount of the equivalent acid of Compound (I).

Preferably, the pharmaceutical composition described in the preceding paragraph also has an effective amount of a Stabilizer. The Stabilizer is at least one pharmaceutically acceptable compound selected from solid sugars and sugar-alcohols, more preferably at least one compound selected from mannitol, xylitol, sorbitol, glucose, fructose, lactose and maltose. Mannitol is the most preferred Stabilizer ingredient.

The amount of the Stabilizer varies with the kind of Stabilizer and the concentration of Compound (I), and may be 40% to 500% (w/w), preferably from 50% to 300% (w/w), more preferably from 50 to 250 % (w/w), most preferably from 50% to 200% (w/w) of the amount of the equivalent acid of Compound (I).

Without departing from the object and scope of the present invention, other pharmaceutically acceptable additive agents may optionally be added to the preparations of the present invention. Where a solution according to the invention is prepared for injection, an isotonizing agent, a soothing agent or other additives may be added thereto.

Preferably, the pharmaceutical compositions described above are salt-free except for the Active Ingredient, the Solubilizer and the Stabilizer.

Lyophilized Compositions of the Invention:

Preferably, the pharmaceutical compositions described in the preceding section are lyophilized. Most preferably the lyophilized composition is prepared with an annealing step by employing the collapse temperature characteristics of Compound (I).

The lyophilized composition contains Solubilizer from about 1 to about 200% (w/w) of the amount of the equivalent acid of

Compound (I). The proportions of the Solubilizer are the same as those set out in the preceding section for the pharmaceutical composition. When the Solubilizer is disodium EDTA (or its acid or other salts) it is preferably used from about 1% to about 15% (w/w) of the amount of the equivalent acid of Compound (I). When the Solubilizer is trisodium citrate dihydrate it is preferably used from about 10% to about 100% of the amount of Active Ingredient.

The identity and proportions of Stabilizer are the same as those set out in the preceding section for the pharmaceutical composition. Mannitol is most preferred as the Stabilizer ingredient of the lyophilized compositions of the invention.

Table 1 lists Specific Preferred Lyophilized Compositions of the Invention (all amounts in milligrams):

Table 1

A.I.	Na Citrate	Mannitol	EDTA
105.8	50	200	--
105.8	100	200	--
105.8	75	200	--
105.8	--	200	1
105.8	--	200	8
105.8	--	200	15

A.I. = Active Ingredient, Na Citrate = trisodium citrate dihydrate
EDTA = ethylenediaminetetraacetic acid, disodium salt

Preferably, the solid lyophilized compositions of the invention are substantially salt-free, except for Compound (I) and the Stabilizer and Solubilizer contained therein.

The lyophilized pharmaceutical formulation can be dissolved in a pharmaceutically acceptable carrier, such as sterile water, sterile water optionally containing saline and/or sterile water containing sugars. For example, for intravenous injection the compositions of the invention may be dissolved in at a concentration of 2 mg/ml in a 4% dextrose/0.5% Na citrate aqueous solution.

As used herein, the terms "lyophilized compositions", "pharmaceutical compositions" and "pharmaceutical preparations" refer to all preparations described in "General rules for preparation" in the Japanese Pharmacopoeia, preferably those that are solutions and injection preparations, more preferably solutions for injection and lyophilized preparations for injection.

Method of Making the Lyophilized Compositions of the Invention:

The lyophilized compositions of the present invention refer to a preparation prepared by freeze drying a solution containing Compound (I), optionally being subjected to a heat treating process, and being dried in a high vacuum for sublimating water. Such lyophilized preparations include lyophilized preparations for injection as mentioned above. The lyophilized preparation may be produced by conventional methods including tray lyophilization, spray lyophilization and vial lyophilization methods. Vial lyophilization is advantageous for preparing multi-dosage units of the invention as described, *infra*.

In order to obtain a solution of Compound (I) by the process of the present invention, Compound (I), a Solubilizer and a solvent are mixed and stirred until the mixture becomes clear. The solvent is preferably an aqueous solvent such as water, purified water, water for injection, isotonic sodium chloride solution or glucose injection as described in the Japanese Pharmacopoeia, more preferably a salt-free aqueous solvent such as water, purified water, water for injection or glucose solutions for injection.

Alternatively, a suitable solvent for forming a solution from the composition of the invention is any injectable solution as further exemplified by those described in The United States Pharmacopoeia (1995, ISBN 0195-7996), for example, "Sterile Water for Injection", "Dextrose and Sodium Chloride Injection",

"Dextrose Injection", "Mannitol Injection" or "Mannitol in Sodium Chloride Injection."

In order to obtain a lyophilized preparation of Compound (I) by the process of the present invention, first, a processing solution prior to lyophilization is prepared. The processing solution before lyophilization is a solution prepared by mixing and stirring Compound (I), a Solubilizer and a solvent, preferably Compound (I), a Solubilizer, a Stabilizer and a solvent, until the mixture becomes clear. For the sequence of addition of the ingredients to the solvent it is highly preferred to first dissolve the Solubilizer and Stabilizer, and thereafter dissolve Compound (I). The solvent is preferably an aqueous solvent such as previously set out above and as described in the Japanese Pharmacopoeia, and more preferably a salt-free aqueous solvent such as water, water for injection or glucose injection. The processing solution before lyophilization of Compound (I) may contain Compound (I) at a concentration of from about 0.5% to 2% (w/w).

If desired, the processing solution before lyophilization may be subjected to a filtration process. The filtration process includes, for example in the case of injection preparations, a sterilizing filtration and/or an ultra filtration of the processing solution before lyophilization to eliminate microorganisms or other contaminating matter from the processing solution before lyophilization.

If desired, the processing solution before lyophilization may be subjected to a distributing process. The distributing process includes, for example in the case of vial lyophilizations, a process distributing a suitable volume of the processing solution before lyophilization into vials taking the concentration of Compound (I) into consideration in order that vial products carry a desired amount of Compound (I).

A lyophilization process is performed as follows:

Preferably, the lyophilized composition is prepared by a sequential heating and cooling process. A process for preparing a lyophilized composition comprises the sequential steps of:

- (a) dissolving lyophilized composition ingredients comprising Sodium [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-phenylmethyl)-1H-indol-4-yl]oxy]acetate, Solubilizer, and Stabilizer in an aqueous solvent;
- (b) cooling the processing solution of step (a) to a temperature below -33 °C;
- (c) heating the product of step (b) to a temperature above -33 °C;
- (d) cooling the product of step (c) to a temperature below -33 °C;
- (e) heating the product of step (d) to a temperature above -13 °C, under subatmospheric pressure for a time sufficient to remove water from the aqueous solvent and yield a solid lyophilized product.

Preferably, step (a) is conducted by dissolving in an aqueous solvent: Sodium [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-phenylmethyl)-1H-indol-4-yl]oxy]acetate; Solubilizer selected from citric acid, edetic acid, polyphosphoric acid and their salts, the amount of which is 1 to 100 % (w/w) of the amount of the equivalent acid of Compound (I); and Stabilizer selected from mannitol, xylitol, sorbitol, glucose, fructose, lactose and maltose, the amount of which is 50 to 200 % (w/w) of the equivalent acid of Compound (I). Moreover, each of steps (b), (c), (d) and (e) is preferably conducted for a period of at least one-half hour, and step (e) is performed at a subatmospheric pressure less than about 133 Pa (1000 milliTorr).

Preferred parameters in the lyophilization process are those wherein Compound (I) is frozen by cooling to -35°C to -45°C . This cooling step is performed preferably over 2 to 4 hours. This process is herein after referred to as the "primary freezing process".

If desired, the frozen solution obtained in the primary freezing process is then warmed to -5°C to -25°C preferably from -10°C to -20°C . This warming step is performed over 3 hours, preferably from 5 to 10 hours. This process is herein after referred to as the "heat treating process".

The composition obtained in the heat treating process is re-frozen, preferably from -35°C to -45°C . This cooling step is performed preferably over 2 to 4 hours. This process is herein after referred to as the "re-freezing process".

The composition obtained through the primary freezing process, the heat treating process and the re-freezing process, is dried under a high vacuum by sublimating water according to methods known to those skilled in the art. Thus, a lyophilized preparation of the present invention is obtained. If desired, two step drying in which the temperature and the degree of vacuum are different may be performed for completely removing water. This process is herein after referred to as the "drying process". If the two step drying is performed, these process are referred to as the "primary drying" process and the "secondary drying" process.

The lyophilization process removes most of the water originally present, but the final product lyophilized composition may contain some free water. Typically, the water content can range from 0.5% to 5.0% weight percent. More typically, the water content ranges from 0.8% to 2.0%.

Dose-concentrate and Unit Dosage Configurations of the Invention:

A dose-concentrate configuration of the formulation of the invention is a sealed container holding an amount of lyophilized pharmaceutical formulation of the invention employed over a standard treatment interval such as 12 or 24 hours. The dose-concentrate configuration is prepared by placing lyophilized composition in a container (e.g., glass or plastic bottles, vials, ampoules) in sufficient amount to treat a mammal for a period ranging from 1 hour to 1 week, but preferably from 4 hours to 48 hours. The container preferably also contains an empty space of sufficient size to permit (i) addition of aqueous solvent plus (ii) additional space as necessary to permit agitation and effect complete solution of the lyophilized composition in the added aqueous solvent. The container may be equipped with a penetrable top, for example, a rubber seal, so that aqueous solvent may be added by penetrating the seal with a hypodermic syringe and the concentrate subsequently removed by the same means.

An example of a dose-concentrate configuration is a glass vial having a capacity of from about 10 to about 100 milliliters containing 50 to 5000 milligrams of lyophilized pharmaceutical composition. A specific example, is a 20 glass bottle with a rubber seal having lyophilized pharmaceutical composition containing 105.8 mg of Compound (I), 50 mg of trisodium citrate dihydrate, and 200 mg of mannitol. The empty space above the solid composition has ample room for addition of a solvent such as sterile water for injection plus room to agitate the total contents.

The addition of the aqueous solvent to the dose-concentrate configuration results in a liquid concentrate which may then be conveniently used to form unit dosages of liquid pharmaceutical formulations by removing aliquot portions or entire contents for dilution as set out in the following section.

Unit Dose of the Invention:

The concentrated solution of lyophilized composition formed in the dose-concentrate container (typically of a bright yellow color) is added to an IV (intravenous) container containing a suitable aqueous solvent. Useful solvents are standard solutions for injection as previously described (e.g., 5% dextrose or sterile water for injection, etc.). Typical unit dosage IV bags are conventional glass or plastic containers having inlet and outlet means and having standard (e.g., 250 ml and 500 ml) capacities. The concentrated solution of lyophilized pharmaceutical formulation is added to the unit dose IV bag in an amount to achieve a concentration of about 0.05 to 2.0 mg of Compound (I) per ml and preferably from 0.2 to 0.8 mg per ml.

Without departing from the object and scope of the present invention, other pharmaceutically acceptable additive agents may be added to the lyophilized preparations of the present invention. Where the lyophilized preparation is to be used for injection, an isotonicizing agent or a soothing agent or other additives may be added thereto.

Use of the Composition of the Invention for Treatment of Inflammatory Diseases:

The improved method of treatment using the lyophilized composition may be practiced as follows:

The diluted formulations of this invention are given by injection, either subcutaneously or into muscle tissue or by injection into a vein. Intravenous injection is the preferred mode of delivery to the mammal being treated and offers the advantage of a quick effect and rapid access into the circulation system, particularly in emergency situations.

Preferably the lyophilized pharmaceutical formulation of this invention is diluted with aqueous solvent suitable for injection and a liquid unit dosage form prepared (viz., IV Bag) for administration to a mammal. An IV bag for pediatric use may have a 100 ml capacity.

It may be appreciated that it may be necessary to make routine variations to the dosage depending on the age and condition of the patient. The specific dose of a compound administered according to this invention to obtain therapeutic or prophylactic effects will, of course, be determined by the particular circumstances surrounding the case, including, for example, the compound administered, the route of administration and the condition being treated. Typical daily doses will contain a non-toxic Compound (I) dosage level of from about 0.01 mg/kg to about 50 mg/kg of body weight of an Active ingredient of this invention.

This invention is a method of treating or preventing sepsis by administering to a mammal in need thereof a therapeutically effective amount of a solution prepared by dissolving the pharmaceutical formulation of this invention. The administration to a septic patient may be either continuous or intermittent.

The decision to begin the therapy for sepsis will be based upon the appearance of the clinical manifestations of sepsis or laboratory tests which show initiation of the sepsis cascade (inclusive of renal complications or coagulation abnormalities or multiple organ failure). Typical clinical manifestations are fever, chills, tachycardia, tachypnea, altered mental state, hypothermia, hyperthermia, accelerated or repressed breathing or heart rates, increased or decreased white blood cell count, and hypotension. These and other symptoms are well known in the art as set out in standard references such as, Harrison's Principles of Internal Medicine (ISBN 0-07-032370-4) 1994, pages 511-515.

The decision to determine the length of therapy may be supported by standard clinical laboratory results from commercially available assays or instrumentation supporting the eradication of the symptoms defining sepsis. The method of the invention may be practiced by continuously or intermittently administering a therapeutically effective dose of the solution prepared from the lyophilized pharmaceutical formulation for as long as deemed efficacious for the treatment of the septic episode. The administration can be conducted for up to a total of about 60 days with a preferred course of therapy lasting for up to 10 days.

The decision to end therapy by the method of the invention may be supported by standard clinical laboratory results from commercially available assays or instrumentation or the disappearance of clinical symptoms characteristic of sepsis. The therapy may be restarted upon the return of sepsis.

Pediatric forms of sepsis are also successfully treated by the methods and compositions of this invention.

Examples

The present invention is more specifically described and explained by, but in no way limited to, the following Examples:

Example 1 and Comparative Example 1:

Solutions were prepared by mixing the materials of Table 2 with a solvent, the solvent being one of water for injection, isotonic sodium chloride solution and 5% glucose solution at a volume of 20 ml.

Table 2 Preparation of solutions

	Comparative Example 1-1	Example 1-1	Example 1-2	Example 1-3	Example 1-4	Example 1-5
A.I.	20 mg	20 mg	20 mg	20 mg	20 mg	20 mg
Na Citrate		4 mg	8 mg	12 mg	16 mg	20 mg

A.I. = Active Ingredient, Na Citrate = trisodium citrate dihydrate

Tests for solubility were performed by inspecting the solutions immediately after being prepared and after 24 hours of storage at room temperature with the unaided eyes. Tables 3 to 5 show the results of the test for solubility. Each table shows clearly that addition of the Solubilizer of the present invention improves stability of the solution.

Table 3 Result of solubility tests (added 20 ml of water 1 to the preparation of Table 1)

	Comparative example 1- 1-20W	Example 1-1-20W	Example 1-2-20W	Example 1-3-20W	Example 1-4-20W	Example 1-5-20W
Initial	0-Δ	0	0	0	0	0
Storage for 24 hours	Δ	0-Δ	0	0	0	0

Table 4 Result of solubility tests (added 20 ml of saline 2 to the preparation of Table 1)

	Comparative example 1- 1-20S	Example 1-1-20S	Example 1-2-20S	Example 1-3-20S	Example 1-4-20S	Example 1-5-20S
Initial	0-Δ	0	0	0	0	0
Storage for 24 hours	Δ	0	0	0	0	0

Table 5 Result of solubility tests (added 20 ml of glucose soln. 3 to the preparation of Table 1)

	Comparative Example 1- 1-20G	Example 1-1-20G	Example 1-2-20G	Example 1-3-20G	Example 1-4-20G	Example 1-5-20G
Initial	Δ	0	0	0	0	0
Storage for 24 hours	Δ	0	0	0	0	0

Explanation of symbols in Tables 2 to 4

0 ... Excellent solution

Δ Crystals appeared slightly in solution

1 water ... water for injection

2 saline ... isotonic sodium chloride solution

3 glucose soln. --- 5% glucose solution

Examples 2 - 4 & Comparative Example 2:

The processing solution before lyophilization was prepared by dissolving the materials of Table 6 in water for injection as a solvent as described in the Japanese Pharmacopoeia such that the concentration of Compound (I) was 10 mg/g. The processing solution before lyophilization was subjected to a sterilizing filtration using a membrane filter of which the pore size was 0.22 micrometer and then distributed in glass vials.

The lyophilization was performed as follows. The primary freezing process was done for 3 hours at -40 °C, the heat treating process for 10 hours at -10 °C, and the re-freezing process for 3 hours was at -40 °C. Then, the primary drying process was performed for 24 hours at 0 °C, 2.0 Pa and the secondary drying process for 5 hours at 60 °C, 2.0 Pa. Thus, lyophilized

preparations of Examples 2 to 4 were obtained. For comparison, the preparation of Comparative example 2 was produced by the method in which the filtration process and the distribution process was the same as those of Examples 2 - 4 and the lyophilization was substantially the same as the process of Examples 2 - 4, that is the primary freezing process was done for 3 hours at -40 °C, the primary drying step for 20 hours at 10 °C, 10 Pa, and the secondary drying step for 5 hours at 40 °C, 2.0 Pa.

Table 6 Composition of lyophilized preparations (in 1 vial)

	Example 2	Example 3	Example 4	Comparative example 2
A.I.	53 mg	53 mg	53 mg	100 mg
Na Citrate	20 mg	20 mg	20 mg	
Mannitol	-	25 mg	50 mg	

A.I. = Active Ingredient, Na Citrate = trisodium citrate dihydrate

Table 7 shows the appearance of the lyophilization cakes immediately after lyophilization in Examples 2 to 4. Addition of the Stabilizer of the present invention gave excellent lyophilized preparations in which the lyophilized cake does not have cracked parts, shrunken parts and a thin layer on the surface of the cake and in which the cake was not colored much.

Table 7 Appearance of cake after lyophilization

	Example 2	Example 3	Example 4	Comparative Example 2
Cake on the Upside of Vial	None	None	None	Some
Color	Yellow	Light yellow	Dark white	Dark yellow
Appearance of cake	Shrunkened Parts on The surface Of cake	Shrunkened parts on the surface of cake	Excellent Cake ¹	Cracked and Shrunkened Cake

¹ This cake does not have cracked parts, shrunkened parts and a thin layer on the surface of cake.

A content uniformity test on Compound (I) of 10 vials of the lyophilized preparation obtained in Example 4 was performed. The content of Compound (I) was measured by the HPLC method. The content of Compound (I) in one vial was 99.0% to 103.4% relative to the theoretical value of the amount of Compound (I), which indicates the lyophilized preparation of the present invention has satisfactory uniformity of content.

The reconstitution times of 10 vials of the lyophilized preparation obtained in Example 4 were measured. The measurement of reconstitution time was performed by adding the sample to 10 ml of water for injection, shaking the resulting mixture at 200 times/min., and measuring the period of time until the samples were completely dissolved. The time of reconstitution was from 7 to 18 seconds. The lyophilized preparation of the present invention has a satisfactory reconstitution property.

Three hermetic vials of the lyophilized preparation of Example 2 were tested with respect to storage stability at 60°C for 2

months. The residual percentages of content in 3 vials were all 99% relative to initial value immediately after lyophilization. The lyophilized preparation of the present invention has satisfactory storage stability.

Example 5:

The processing solution before lyophilization was prepared by dissolving the materials of Table 8 in water for injection as a solvent as described in the Japanese Pharmacopoeia such that the concentration of Compound (I) was 15 mg/g. The processing solution before lyophilization was subjected to a sterilizing filtration using a membrane filter of which the pore size was 0.22 micrometer and then distributed in glass vials.

Table 8 Composition of lyophilized preparations (in 1 vial)

	Example 5
A.I.	127 mg
Na Citrate	36 mg
Mannitol	180 mg

A.I. = Active Ingredient, Na Citrate = trisodium citrate dihydrate

The lyophilization was performed as follows. The primary freezing step was done for 3 hours at -40 °C, the heat treating step for 10 hours at -10 °C, and the re-freezing step for 3 hours at -40 °C. Then, the primary drying step was performed for 60 hours at 0 °C, 10 Pa and the secondary drying step for 5 hours at 60 °C, 4 Pa. Thus the lyophilized preparation of Example 5 was obtained.

The appearance of cake immediately after lyophilization in Example 5 was observed. The lyophilized cake did not have cracked parts, shrunk parts and a thin layer on the surface of cake and the color of the cake was dark white.

The content uniformity test on Compound (I) of 10 vials of the lyophilized preparation obtained in Example 5 was performed. The content of Compound (I) was measured by the HPLC method. The content of Compound (I) per vial was 99.8 to 101.3 % relative to the theoretical value of the amount of Compound (I), which indicates the lyophilized preparation of the present invention has satisfactory uniformity of content.

The reconstitution time of 10 vials of the lyophilized preparation obtained in Example 5 was measured. The measurement of reconstitution time was performed by adding 10 ml of water for injection to each of the vials, shaking the resulting mixture at 200 times/min., and measuring the period of time until the cake was completely dissolved. The time of reconstitution was from 22 to 29 seconds. The lyophilized preparation of the present invention has a satisfactory reconstitution property.

Example 6:

Another example of preparing the lyophilized composition of the invention is as follows:
Preparation of a solution suitable for lyophilization (processing solution):

(A) A volume of water equal to approximately 80% of the final volume of solid lyophilized pharmaceutical composition was placed in the manufacturing vessel.

(B) Mannitol and sodium citrate were first added to the vessel and stirred until complete dissolution took place.

(C) Sodium [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetate was added to the vessel and stirred until completely dissolved.

(D) The remaining water was added to achieve a final Active Ingredient concentration of 10 mg per ml.

The sequential process of lyophilization was performed as follows:

1. Sealable vials containing 10 ml of the processing solution prepared in the preceding step of this example were placed on the shelves of a freeze dryer pre-cooled to 0 °C.

2. After all the vials had been loaded onto the shelves, the shelf temperature was cooled to -40°C. Once product temperature of the monitored vials is -40°C, the vials were held at this temperature for 2 hours.

3. The shelf temperature was then raised to -10°C to anneal the frozen solution. This temperature was above the collapse temperature of the solution which permitted the crystallization of the solutes. The product was held at this temperature for several hours.

4. Shelf temperature was then decreased to -40°C again for a short period of time to complete the annealing (temperature cycling) process.

5. Primary drying was then initiated by increasing shelf temperature to 0°C and decreasing chamber pressure to approximately 13.3 Pa (100 milliTorrr). Primary drying lasted for more than 24 hours until product temperature begins to rise, signaling that solvent water has been removed.

6. Secondary drying was achieved by raising the chamber temperature to 28°C with chamber pressure remaining at 13.3 Pa. (100 milliTorrr) and lasting for several hours. The product was a solid uncracked cake of a off-white color.

As the above Examples show, the present invention provides pharmaceutical compositions of Compound (I) which are stable and have good reconstitution properties.

It will be apparent to those skilled in the art that various modifications and variations can be made to the compositions and processes of this invention. Thus, it is intended that the present invention cover such modifications and variations, provided they come within the scope of the appended claims and their equivalents.

The disclosure of all publications cited above are expressly incorporated herein by reference in their entireties to the same extent as if each were incorporated by reference individually.

What Is Claimed Is:

1. A pharmaceutical composition which comprises Sodium [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-phenylmethyl)-1H-indol-4-yl]oxy]acetate as Active Ingredient and a chelating agent as a Solubilizer.
2. A pharmaceutical composition as claimed in claim 1 wherein the chelating agent is at least one compound selected from the group consisting of citric acid, edetic acid, polyphosphoric acid and their salts.
3. A pharmaceutical composition as claimed in claim 1 wherein the chelating agent is sodium citrate.
4. A pharmaceutical composition as claimed in claim 1 wherein the amount of the chelating agent is from 1% to 400% (w/w) of the amount of the equivalent acid of Active Ingredient.
5. A pharmaceutical composition as claimed in claim 3 wherein the amount of sodium citrate is from 10% to 100% (w/w) of the amount of the equivalent acid of Active Ingredient.
6. A pharmaceutical composition as claimed in claim 1 which is salt-free except for the Active Ingredient and the chelating agent.
7. A pharmaceutical composition as claimed in claim 1 which is lyophilized.

8. A pharmaceutical composition as claimed in claim 7 which further comprises at least one compound selected from the group consisting of solid sugars and sugar-alcohols, as a Stabilizer.

9. A pharmaceutical composition as claimed in claim 8 wherein the Stabilizer is at least one compound selected from the group consisting of mannitol, xylitol, sorbitol, glucose, fructose, lactose and maltose.

10. A pharmaceutical composition as claimed in claim 8 wherein the Stabilizer is mannitol.

11. A pharmaceutical composition as claimed in claim 8 wherein the amount of the Stabilizer is from 40% to 500% (w/w) of the amount of the equivalent acid of Active Ingredient.

12. A lyophilized composition which comprises sodium [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-phenylmethyl]-1H-indol-4-yl]oxy]acetate as Active Ingredient, a Stabilizer and a Solubilizer.

13. The composition of claim 12 wherein the Solubilizer is selected from at least one compound selected from citric acid, edetic acid, polyphosphoric acid and their salts; and the Stabilizer is selected from at least one compound selected from the group consisting of mannitol, xylitol, sorbitol, glucose, fructose, lactose and maltose.

14. The composition of claim 12 wherein the Solubilizer is sodium citrate dihydrate or disodium EDTA; and the Stabilizer is mannitol.

15. The composition of claim 12 wherein per the amount of the equivalent acid of Active Ingredient, the Stabilizer is present at 1 to 100 % (w/w) and the Solubilizer is present at 50 to 200 % (w/w).

16. The composition of any one of Claims 12 or 13 or 14 or 15 which is salt-free, except for Active Ingredient, Solubilizer and Stabilizer.

17. A method of making the pharmaceutical formulation of the invention, comprising the steps of:

a) dissolving a composition comprising Sodium [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-phenylmethyl)-1H-indol-4-yl]oxy]acetate, Solubilizer, and Stabilizer in an aqueous solvent;

b) cooling the processing solution of step (a) to a temperature below about -33 °C;

c) heating the product of step (b) to a temperature above about -33 °C;

d) cooling the product of step (c) to a temperature below about -33°C;

e) heating the product of step (d) to a temperature above -13° C, under subatmospheric pressure for a time sufficient to remove water from the aqueous solvent and yield a solid lyophilized product.

18. The process of claim 17 wherein:

Step (a) is conducted by dissolving in an aqueous solvent: Sodium [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-phenylmethyl)-1H-indol-4-yl]oxy] acetate; Solubilizer selected from citric acid, edetic acid, polyphosphoric acid and their salts, the amount of which is 1 to 100 % (w/w) of the amount of the equivalent acid of Active Ingredient; and Stabilizer selected from mannitol, xylitol, sorbitol, glucose, fructose, lactose and maltose, the amount of which is 50 to 200 % (w/w) of the amount of the equivalent acid of Active Ingredient.

19. The process of claim 17 wherein:

Steps (b), (c), (d) and (e) are each conducted for a period of at least one-half hour and step (e) is performed at a subatmospheric pressure less than 133 Pa (1000 milliTor).

20. A lyophilized composition prepared by the process of Claim 17.

21. A method of inhibiting sPLA₂ mediated release of fatty acid which comprises contacting sPLA₂ with a therapeutically effective amount of a solution prepared from the composition of claim 1 or 12.

22. A method of treating a mammal, including a human, to alleviate the pathological effects of Inflammatory Diseases; wherein the method comprises parenterally administering to said mammal a therapeutically effective amount of a solution prepared from the formulation of claim 1 or 12.

23. A method for the treatment or prevention of sepsis comprising administering a therapeutically effective amount of an aqueous solution comprising

- (a) Sodium [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-phenylmethyl)-1H-indol-4-yl]oxy]acetate,
- (b) Trisodium Citrate Dihydrate, and
- (c) Mannitol.

24. A lyophilized composition of claim 1 or 12 for the manufacture of a medicament for treating sepsis in a mammal, including a human, currently afflicted with or susceptible to sepsis.

25. A dose-concentrate containing sealed container containing lyophilized composition of Claim 1 or 12, said container having a space sufficient for introduction of a volume of aqueous solvent sufficient to form a concentrated solution of said formulation.

26. A unit dose IV bag or IV bottle suitable for containing a liquid for intravenous injection in the treatment of Inflammatory Diseases wherein the improvement comprises; filling the bag with an aqueous solution prepared from the composition of claim 1 or 12.

27. Lyophilized compositions for the treatment of Inflammatory Diseases as described by any of the Examples herein.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 99/04516

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K31/40 A61K47/12 A61K47/26

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 0 675 110 A (LILLY CO ELI) 4 October 1995 cited in the application see page 34, line 4-41	1-27
Y	DR. FIEDLER: "LEXIKON DER HILFSSTOFFE FÜR PHARMAZIE, KOSMETIK UND ANGRENZENDE GEBIETE, Bd. 1, P. 309-311" 1989, EDITIO CANTOR, AULENDORF, GERMANY XP002105792 See "Citronensäure"	1-27
Y	DR. FIEDLER: "LEXIKON DER HILFSSTOFFE FÜR PHARMAZIE, KOSMETIK UND ANGRENZENDE GEBIETE; BD.2, P. 751-755" 1989, EDITIO CANTOR, AULENDORF, GERMANY XP002105793 See "Lösungsvermittler"	1-27



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

14 June 1999

Date of mailing of the international search report

06/08/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Herrera, S

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/04516

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0675110 A	04-10-1995	AU 688458 B	12-03-1998
		AU 1621795 A	12-10-1995
		BR 9501404 A	05-03-1996
		CA 2146097 A	02-10-1995
		CN 1114310 A	03-01-1996
		CZ 9500822 A	13-12-1995
		FI 951553 A	02-10-1995
		HU 72048 A	28-03-1996
		JP 7285933 A	31-10-1995
		NO 951252 A	02-10-1995
		NZ 270848 A	26-05-1997
		PL 307951 A	02-10-1995
		US 5654326 A	05-08-1997
		US 5733923 A	31-03-1998
		ZA 9502693 A	30-09-1996